News | June 13, 2023
Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
UTD2 is the world's first oral epothilone microtubule inhibitor
UTD2 is the world's first oral epothilone microtubule inhibitor
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Strategies aimed at solving the current overdose epidemic must go beyond the identification of risk
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Subscribe To Our Newsletter & Stay Updated
